$ABCL

AbCellera (Nasdaq: ABCL) said it will report top-line results from its Phase 2 trial of ABCL635 for moderate-to-severe vasomotor symptoms due to menopause before market open on Aug. 10, 2026, and hold a conference call at 4:30 a.m. PT. The randomized, double-blind, placebo-controlled study enrolled about 80 postmenopausal women.

AbCellera (Nasdaq: ABCL) reported Q2 2026 results. Net loss was $55.4 million versus $34.7 million in Q2 2025, with revenue of $4.1 million versus $17.1 million. R&D was $46.0 million and SG&A $13.9 million. The company said Phase 2 ABCL635 top-line data is expected in August 2026 and reported $565 million in cash and marketable securities.

AbCellera Biologics Inc. (ABCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningspressrelease.htm EX-99.1 Document NEWS RELEASE AbCellera Reports Q2 2026 Business Results 8/5/2026 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2026. All financial infor

The article says Canada’s biotech sector has seen a strong 12-month run, with listed companies raising $2.4 billion on public markets and excluding Apotex’s $1.5 billion June IPO. It highlights several Canadian biotechs, especially AbCellera Biologics, which plans to report key human efficacy results this quarter for a menopause hot-flash treatment. It also notes foreign investors dominate funding.

The article says AbCellera Biologics (AbCellera) has seen its Nasdaq debut in 2020 followed by a stock decline, and it expects this quarter to release efficacy data for a menopause hot-flash treatment. The company targets US$1 billion-plus peak annual sales if successful and plans more clinical trials and antibody partnerships. It also links biotech M&A and IPO activity to a global patent-cliff.

AbCellera (ABCL) said it has entered a drug discovery collaboration with Vertex Pharmaceuticals (VRTX) to identify and conduct early research on T-cell engagers aimed at autoimmune disease conditions. AbCellera expects to use its discovery platform as part of the work, according to the company.

AbCellera (Nasdaq: ABCL) said it will collaborate with Vertex Pharmaceuticals (Nasdaq: VRTX) to discover, develop, manufacture and commercialize multispecific T-cell engagers for autoimmune diseases and other conditions. Vertex will fund R&D. AbCellera will receive $28 million upfront plus milestone payments and royalties, with potential Phase 1 manufacturing support.

AbCellera Biologics Inc. (ABCL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. abcl-20260630 0001703057 false Vancouver BC 0001703057 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________ FORM 8-K __________________________________________ CURRENT REPORT PURSUANT TO SECTION 1

AbCellera (Nasdaq: ABCL) said it appointed Dr. Lynn Seely, an independent director, to its board. AbCellera cited her leadership in biopharma, including her current role as president/CEO of Lyell Immunopharma and prior leadership at Myovant Sciences and Medivation. The company said the appointment supports its antibody-medicine development pipeline.

Indian markets’ June 15 watchlist includes Vedanta’s four demerged units—Vedanta Aluminium, Vedanta Oil & Gas, Vedanta Power and Vedanta Iron & Steel—starting trading on June 15. JSW Energy’s unit commissioned a 150 MW Tidong project; it also agreed to acquire Maruti Clean Coal & Power for Rs 1,410 crore. ONGC Petro Additions (OPaL) approved up to Rs 4,471 crore via NCDs.